Company Profile
Aligos Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Aligos Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aligos Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Aligos Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Aligos Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
ALGS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Aligos’s catalysts are hepatitis and liver-disease programs, plus any update that clarifies whether the company’s antiviral platform still has a path. The stock needs a more concrete clinical step.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Source: Aligos Therapeutics
- 02
- 03
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Source: Aligos Therapeutics
- 04
- 05
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
Source: Aligos Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.